Follow-on drugs: How far should chemists look?

Drug Discovery Today

Volumn 16, Issue 15-16, 2011, Pages 722-732

  Giordanetto, Fabrizio ^a   Boström, Jonas ^a   Tyrchan, Christian ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AREDIA IV; AZITHROMYCIN; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DONEPEZIL; ETIDRONIC ACID; GREPAFLOXACIN; ISOTRETINOIN; METRONIDAZOLE; NIFEDIPINE; NORFLOXACIN; OCTREOTIDE; PAMIDRONIC ACID; PRAZOSIN; PROPRANOLOL; RASAGILINE; RETINOIC ACID; RITONAVIR; SAQUINAVIR; SELEGILINE; SPARFLOXACIN; TACRINE; TAMOXIFEN CITRATE; TERAZOSIN; TIMOLOL MALEATE; TINIDAZOLE; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

DRUG APPROVAL; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; PHARMACODYNAMICS; REVIEW;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80051672475     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.05.011     Document Type: Review

References (58)

1. Cockburn, I.M. Is the pharmaceutical Industry in a Productivity Crisis? http://ideas.repec.org/h/nbr/nberch/0032.html
2. M. Williams Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J. Pharmacol. Exp. Ther. 336 2011 3 8
3. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. M. Angell The Truth About the Drug Companies: How They Deceive Us and What to Do About It 2004 Random House
5. A. Hollis Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development" Pharmacoeconomics 3 2005 1187 1192 (Pubitemid 41803314)
6. A. Werthheimer Too many drugs? The clinical and economic value of incremental innovations Res. Hum. Cap. Dev. 14 2001 77 118
7. Z.J. Lu, and W.S. Comanor Strategic pricing of new pharmaceuticals Rev. Econ. Stat. 80 2008 108 118
8. A. Towse, and T. Leighton J. Sussex, N. Marchant, Risk and Return in the Pharmaceutical Industry 1999 Office of Health Economics 91 105
9. J.A. DiMasi Price Trends for Prescription Pharmaceuticals: 1995-1999 2000 US Department of Health and Human Services website: http://aspe.hhs.gov/health/ reports/Drug-papers/dimassi/dimasi-final.htm
10. T.H. Lee "Me-too" products - friend or foe? N. Engl. J. Med. 350 2004 211 212
11. E.F. Schmid, and D.A. Smith Is declining innovation in the pharmaceutical industry a myth? Drug Discov. Today 10 2005 1031 1039 (Pubitemid 41074141)
12. Maass ReCore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations J. Chem. Inf. Model. 47 2007 390 399 (Pubitemid 46615943)
13. K.D. Stewart Drug Guru: a computer software program for drug design using medicinal chemistry rules Bioorg. Med. Chem. 14 2006 7011 7022 (Pubitemid 44307638)
14. Bergmann SHOP: scaffold HOPping by GRID-based similarity searches J. Med. Chem. 50 2007 2708 2717 (Pubitemid 46896079)
15. Fieldstere, Cresset Group, BioPark Hertfordshire, United Kingdom. http://www.cresset-group.com/products/fieldstere/
16. Brood, OpenEye Scientific Software, Santa Fe, New Mexico, United States. http://www.eyesopen.com/brood
17. Core Hoping, Schrodinger, New York, New York, United States. http://www.schrodinger.com/productsguide/
18. MOE Pharmacophore Tools, Chemical Computing Group, Montreal, Quebec, Canada. http://www.chemcomp.com/journal/scaffold.htm
19. H. Kubinyi Chemical similarity and biological activities J. Braz. Chem. Soc. 13 2002 717 726 (Pubitemid 36181535)
20. G.M. Maggiora On outliers and activity cliffs - why QSAR often disappoints J. Chem. Inf. Model. 46 2006 1535 (Pubitemid 44185680)
21. J.A. DiMasi, and L.B. Faden Competitiveness in follow-on drug R&D: a race or imitation? Nat. Rev. Drug Discov. 10 2011 23 27
22. OEChem - Toolkit Python Manual, OpenEye Scientic Software, Santa Fe, NM. http://www.eyesopen.com
23. Boström Do structurally similar molecules bind in a similar fashion J. Med. Chem. 49 2006 6716 6725 (Pubitemid 44749739)
24. J.A. Grant Lingos, finite state machines, and fast similarity searching J. Chem. Inf. Model. 46 2006 1912 1918 (Pubitemid 44625962)
25. N. Blomberg Design of compound libraries for fragment screening J. Comp. Aid. Mol. Design 23 2009 513 525
26. V.N. Viswanadhan Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics J. Chem. Inf. Comput. Sci. 29 1989 163 172
27. Ghose Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods J. Phys. Chem. A 102 1998 3762 3772 (Pubitemid 128611348)
28. R.P. Sheridan, and S.K. Kearsley Why do we need so many chemical similarity search methods? Drug Discov. Today 7 2002 903 911
29. R. Ferrari How do calcium antagonists differ in clinical practice? Cardiovasc. Drugs Ther. 8 1994 565 575 (Pubitemid 24347242)
30. G. Kryger Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs Structure 7 1999 297 307 (Pubitemid 29159689)
31. M.W. Jann Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors Clin. Pharmacokinet. 41 2002 719 739 (Pubitemid 34948194)
32. C. Merry Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients AIDS 11 1997 29 33
33. K. Holli Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group J. Clin. Oncol. 18 2000 3487 3494
34. G.C. Hard Major difference in the hepatocarciongenicity and DNA adduct forming ability between toemifene and tamoxifen in Crl:CD(BR) rats Cancer Res. 53 1993 4534 4541 (Pubitemid 23304376)
35. M. Parkkari Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study Acta Ophtalmol. Scand. 81 2003 495 499 (Pubitemid 37265670)
36. H.A. Harvey, and A. Hajba Stroke incidence with toremifene is lower than with tamoxifen in breast cancer patients Proc. Am. Soc. Clin. Oncol. 22 2003 741
37. S.H. Ralston Comparison of three intravenous biphosphonates in cancer-associated hypercalcemia Lancet 2 1989 1180 1182 (Pubitemid 19275450)
38. R. Gucalp Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia J. Clin. Oncol. 10 1992 134 142
39. J. Mattila Comparative pharmacokinetics of metronidazole and tinidazole is influenced by administration route Antimicrob. Agents Chemother. 23 1983 721 725 (Pubitemid 13087010)
40. M.D. Nailor, and J.D. Sobel Tinidazole for the treatment of vaginal infections Exp. Opin. Investig. Drugs 16 2007 743 751
41. T.W. Wilson Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade Clin. Pharmacol. Ther. 32 1982 676 685 (Pubitemid 13093837)
42. M.R. Achong Comparison of cardiac effect of timolol and propranolol Clin. Pharmacol. Ther. 18 1975 278 286
43. J.J. Kyncl Pharmacology of terazosin Am. J. Med. 80 1986 12 19 (Pubitemid 16047544)
44. G.W. Amsden Erythromycin, clarithromycin and azithromycin: are the differences real? Clin. Ther. 18 1996 56 72
45. J.M. Zuckerman Macrolides and ketolides: azithromycin, clarithromycin, telithromycin Infect. Dis. Clin. N. Am. 18 2004 621 649 (Pubitemid 39089098)
46. J.M. Domagala Structure-activity and structure-side-effect relationships for the quinolone antibacterials J. Antimicrob. Chemother. 33 1994 685 706 (Pubitemid 24149805)
47. D.A. Henry Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism Br. Med. J. 281 1980 775 777 (Pubitemid 10048547)
48. M. Taniuchi Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population Circulation 104 2001 539 543 (Pubitemid 32738122)
49. A. DiMarco J.W. Corcoran, F.E. Hahn, Antibiotics 1974 Springer-Verlag 101 128
50. F. Arcamone Doxorubicin, anticancer antibiotics S.T. Crooke, S.D. Reich, Medicinal Chemistry Vol. 17 1981 Academic Press
51. J.R. Cove-Smith, and C.A. Kirk CNS-related side-effects with metoprolol and atenolol Eur. J. Pharmacol. 28 1985 69 72 (Pubitemid 16218645)
52. J.D. Winston Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients Lancet 346 1995 69 74
53. A.P. Hill Oral delivery of 5-HT1D receptor agonists: towards the discovery of 311C90, a novel antimigraine agent Headache 34 1995 308
54. P.J. Goadsby, and C.J. Boes Zolmitriptan: differences from sumatriptan Curr. Med. Res. Opin. 17 2001 46 50
55. L. DeSantis Preclinical overview of brinzolamide Survey Ophtalnol. 44 2000 S119 S129
56. J.E. Michaud Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension Am. J. Ophtalmol. 132 2001 235 243
57. C.J. Bailey Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
58. V. Mascitti Discovery of a clinical candidate from the structurally unique diox-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors J. Med. Chem. 2011 10.1021/jm200049r